图光制药
MPLT
7.70
-0.32
-3.99%
图光制药
US · MPLT
#3723 按市值排名
上市于 2025
7.70
-0.32
-3.99%
实时 - 追踪5344个代码 - 心跳于18秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了7.1个百分点。
机构持股
- 机构持股比例
- 94.25% -7.06pp
- 机构数量
- 126 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Private Company48.74%
VC/PE Fund18.98%
Mutual Fund18.84%
Public Company3.82%
Hedge Fund3.82%
Individual/Insider2.41%
Other3.34%
主要股东 截至 2026-09-01
Catalyst4, Inc
45.54% · 25.31M 股
Forbion Capital Partners B.V.
7.97% · 4.43M 股
T. Rowe Price Group, Inc.
7.57% · 4.20M 股
Novo Holdings A/S
3.75% · 2.09M 股
Chen's Group International Limited
2.93% · 1.63M 股
Pivotal BioVenture Partners LLC
2.31% · 1.28M 股
The Goldman Sachs Group, Inc.
1.95% · 1.08M 股
BlackRock
1.84% · 1.03M 股
5AM Venture Management, LLC
1.71% · 950.01K 股
Sanofi
1.64% · 912.04K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 29次买入 · 21次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Catalyst4, Inc | -- | 45.54% |
| Vishwas Setia | Chief Financial Officer | 0.64% |
| Erin Foff | Chief Medical Officer | 0.56% |
| Christopher Kroeger | Chief Executive Officer | 0.47% |
| Robert Malenka | Co-Founder, Director & Member of Scientific Advisory Board | 0.39% |
| Timothy Garnett | Independent Director | 0.12% |
| James Lillie | Chief Scientific Officer | 0.08% |
| George Pavlov | Independent Chairperson | 0.04% |
| Troy Cox | Independent Director | 0.04% |
| Anatol Kreitzer | Chief Discovery Officer | 0.04% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | Kristopher Hanson | General Counsel | Automatic Disposition | -16,509 | $11.67 |
| 2026-08-16 | Christopher Kroeger | Chief Executive Officer | Other Acquisition | +23,145 | -- |
| 2026-08-16 | Christopher Kroeger | Chief Executive Officer | Other Derivative Acquisition | +93,955 | $11.25 |
| 2026-08-16 | Jonathan Gillis | Chief Administrative & Accounting Officer | Other Acquisition | +8,242 | -- |
| 2026-08-16 | Jonathan Gillis | Chief Administrative & Accounting Officer | Other Derivative Acquisition | +27,268 | $11.25 |
| 2026-08-16 | James Lillie | Chief Scientific Officer | Other Acquisition | +7,730 | -- |
| 2026-08-16 | James Lillie | Chief Scientific Officer | Other Derivative Acquisition | +31,395 | $11.25 |
| 2026-08-16 | Kristopher Hanson | General Counsel | Other Acquisition | +7,730 | -- |
| 2026-08-16 | Kristopher Hanson | General Counsel | Other Derivative Acquisition | +31,395 | $11.25 |
| 2026-08-16 | Erin Foff | Chief Medical Officer | Other Acquisition | +13,360 | -- |
| 2026-08-16 | Erin Foff | Chief Medical Officer | Other Derivative Acquisition | +54,240 | $11.25 |
| 2026-08-16 | Anatol Kreitzer | Chief Discovery Officer | Other Acquisition | +6,020 | -- |
| 2026-08-16 | Anatol Kreitzer | Chief Discovery Officer | Other Derivative Acquisition | +24,455 | $11.25 |
| 2026-08-13 | Catalyst4, Inc | -- | Open Market Acquisition | +4,400,000 | $11.38 |
| 2026-08-13 | Catalyst4, Inc | -- | Open Market Derivative Acquisiti | +2,928,686 | $0.00 |
| 2026-08-02 | James Lillie | Chief Scientific Officer | Automatic Disposition | -22,082 | $12.54 |
| 2026-07-29 | Novo Holdings A/S | -- | Intent to Sell (Form 144) | -1,600,000 | $15.02 |
| 2026-07-29 | Catalyst4, Inc | -- | Private Acquisition | +1,000,000 | $13.00 |
| 2026-07-28 | Catalyst4, Inc | -- | Open Market Acquisition | +209,225 | $10.74–12.63 |
| 2026-07-27 | Troy Cox | Independent Director | Open Market Acquisition | +15,620 | $9.52 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
图光制药 讨论区 0 条评论